Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)MOMPARLER, Richard L.Seminars in hematology. 2005, Vol 42, Num 3, pp S9-S16, issn 0037-1963, SUP2Article

Decitabine dosing schedulesKANTARJIAN, Hagop M; ISSA, Jean-Pierre J.Seminars in hematology. 2005, Vol 42, Num 3, pp S17-S22, issn 0037-1963, SUP2Article

Issues regarding study design for initial clinical trials using decitabineDEBAUN, Michael R.Seminars in hematology. 2004, Vol 41, Num 4, pp 23-27, issn 0037-1963, 5 p., SUP6Conference Paper

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)MOMPARLER, Richard L.Seminars in oncology. 2005, Vol 32, Num 5, pp 443-451, issn 0093-7754, 9 p.Article

Decitabine in myelodysplastic syndromesSABA, Hussain I; WIJERMANS, Pierre W.Seminars in hematology. 2005, Vol 42, Num 3, pp S23-S31, issn 0037-1963, SUP2Article

Clinical development of decitabine as a prototype for an epigenetic drug programROSENFELD, Craig S.Seminars in oncology. 2005, Vol 32, Num 5, pp 465-472, issn 0093-7754, 8 p.Article

Decitabine in chronic leukemiasISSA, Jean-Pierre J; BYRD, John C.Seminars in hematology. 2005, Vol 42, Num 3, pp S43-S49, issn 0037-1963, SUP2Article

Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine TherapyJABBOUR, Elias; GARCIA-MANERO, Guillermo; BATTY, Nicolas et al.Cancer. 2010, Vol 116, Num 16, pp 3830-3834, issn 0008-543X, 5 p.Article

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaKANTARJIAN, Hagop M; O'BRIEN, Susan; KEATING, Michael et al.Cancer. 2003, Vol 98, Num 3, pp 522-528, issn 0008-543X, 7 p.Article

Evolution of Decitabine Development : Accomplishments, Ongoing Investigations, and Future StrategiesJABBOUR, Elias; ISSA, Jean-Pierre; GARCIA-MANERO, Guillermo et al.Cancer. 2008, Vol 112, Num 11, pp 2341-2351, issn 0008-543X, 11 p.Article

The Role of Decitabine for the Treatment of Acute Myeloid LeukemiaGANETSKY, Alex.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1511-1517, issn 1060-0280, 7 p.Article

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)CASHEN, Amanda F; SHAH, Ajit K; TODT, Laura et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 5, pp 759-766, issn 0344-5704, 8 p.Article

Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidineTHOTTASSERY, Jaideep V; SAMBANDAM, Vijaya; ALLAN, Paula W et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 291-302, issn 0344-5704, 12 p.Article

Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulationSCHMIEDEL, Benjamin J; ARELIN, Viktor; GRUENEBACH, Frank et al.International journal of cancer (Print). 2011, Vol 128, Num 12, pp 2911-2922, issn 0020-7136, 12 p.Article

Transcriptional reactivation of murine cytomegalovirus ie gene expression by 5-aza-2'-deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoterHUMMEL, Mary; SHIXIAN YAN; ZHIGAO LI et al.Journal of general virology. 2007, Vol 88, pp 1097-1102, issn 0022-1317, 6 p., 4Article

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaARIBI, Ahmed; BORTHAKUR, Gautam; RAVANDI, Farhad et al.Cancer. 2007, Vol 109, Num 4, pp 713-717, issn 0008-543X, 5 p.Article

Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabineCASHEN, Amanda F; DEVINE, Hollie; DIPERSIO, John et al.American journal of hematology. 2006, Vol 81, Num 7, pp 543-545, issn 0361-8609, 3 p.Article

The effect of decitabine on megakaryocyte maturation and platelet releaseJIANHUI WANG; ZANHUA YI; SHIYANG WANG et al.Thrombosis and haemostasis. 2011, Vol 106, Num 2, pp 337-343, issn 0340-6245, 7 p.Article

Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcriptionWEBER, B; KIMHI, S; HOWARD, G et al.Oncogene (Basingstoke). 2010, Vol 29, Num 43, pp 5775-5784, issn 0950-9232, 10 p.Article

P21^WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damageJIEMJIT, A; FANDY, T. E; CARRAWAY, H et al.Oncogene (Basingstoke). 2008, Vol 27, Num 25, pp 3615-3623, issn 0950-9232, 9 p.Article

Superiority of prolonged low-dose azanucleoside administration? : Results of 5-aza-2' -deoxycytidine retreatment in high-risk myelodysplasia patientsRÜTER, Björn; WIJERMANS, Pierre W; LÜBBERT, Michael et al.Cancer. 2006, Vol 106, Num 8, pp 1744-1750, issn 0008-543X, 7 p.Article

Inhibition of methylation decreases osteoblast differentiation via a non-DNA-dependent methylation mechanismVAES, Bart L. T; LUTE, Carolien; VAN DER WONING, Sebastian P et al.Bone (New York, NY). 2010, Vol 46, Num 2, pp 514-523, issn 8756-3282, 10 p.Article

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineLAVELLE, Donald; VAITKUS, Kestis; COVEY, Joseph et al.Blood. 2012, Vol 119, Num 5, pp 1240-1247, issn 0006-4971, 8 p.Article

DNA methylation changes after 5-Aza-2'-deoxycytidine therapy in patients with leukemiaYANG, Allen S; DOSHI, Ketan D; KANTARJIAN, Hagop M et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5495-5503, issn 0008-5472, 9 p.Article

Characterization of dna demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndromeMUND, Cora; HACKANSON, Björn; STRESEMANN, Carlo et al.Cancer research (Baltimore). 2005, Vol 65, Num 16, pp 7086-7090, issn 0008-5472, 5 p.Article